|
2025-03-21 |
2025-03-20 |
PS
Planned sale
|
HENRY CHRISTIAN O
Non-Executive Director
|
10,500
-39.5%
9.77
USD 102,575
|
10,500
-39.5%
|
9.77
|
USD 102,575
|
|
|
2025-03-07 |
2025-03-07 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
169,025
-33.3%
9.57
USD 1,617,569
|
169,025
-33.3%
|
9.57
|
USD 1,617,569
|
|
|
2024-11-27 |
2024-11-25 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
50,000
-18.7%
15.00
USD 750,000
|
50,000
-18.7%
|
15.00
|
USD 750,000
|
|
|
2024-11-15 |
2024-11-15 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
51,234
-19.1%
14.32
USD 733,671
|
51,234
-19.1%
|
14.32
|
USD 733,671
|
|
|
2024-11-13 |
2024-11-08 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
36,000
-100.0%
16.00
USD 576,000
|
36,000
-100.0%
|
16.00
|
USD 576,000
|
|
|
2024-10-18 |
2024-10-16 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
22,500
-100.0%
13.50
USD 303,750
|
22,500
-100.0%
|
13.50
|
USD 303,750
|
|
|
2024-10-18 |
2024-10-16 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
65,625
-100.0%
13.75
USD 902,344
|
65,625
-100.0%
|
13.75
|
USD 902,344
|
|
|
2024-10-18 |
2024-10-16 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
40,997
-100.0%
13.00
USD 532,961
|
40,997
-100.0%
|
13.00
|
USD 532,961
|
|
|
2024-10-18 |
2024-10-16 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
79,714
-100.0%
14.00
USD 1,115,996
|
79,714
-100.0%
|
14.00
|
USD 1,115,996
|
|
|
2024-10-18 |
2024-10-16 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
90,474
-25.2%
15.00
USD 1,357,110
|
90,474
-25.2%
|
15.00
|
USD 1,357,110
|
|
|
2024-10-01 |
2024-09-27 |
B
Purchase
|
GSK plc
Large shareholder
|
2,791,930
+20.0%
8.00
USD 22,335,440
|
2,791,930
+20.0%
|
8.00
|
USD 22,335,440
|
|
|
2024-09-27 |
2024-09-25 |
PS
Planned sale
|
Moran Kyle
Chief Financial Officer
Officer
|
17,146
-46.4%
9.00
USD 154,314
|
17,146
-46.4%
|
9.00
|
USD 154,314
|
|
|
2024-08-23 |
2024-08-21 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
48,366
-11.9%
5.78
USD 279,555
|
48,366
-11.9%
|
5.78
|
USD 279,555
|
|
|
2024-04-05 |
2024-04-03 |
PS
Planned sale
|
Moran Kyle
Chief Financial Officer
Officer
|
15,630
-31.5%
6.17
USD 96,421
|
15,630
-31.5%
|
6.17
|
USD 96,421
|
|
|
2023-12-13 |
2023-12-11 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director
Large shareholder
|
1,000,000
+5.5%
5.00
USD 5,000,000
|
1,000,000
+5.5%
|
5.00
|
USD 5,000,000
|
|
|
2024-01-30 |
2023-12-07 |
B
Purchase
|
GSK plc
Large shareholder
|
3,300,000
+30.9%
5.00
USD 16,500,000
|
3,300,000
+30.9%
|
5.00
|
USD 16,500,000
|
|
|
2023-08-23 |
2023-08-23 |
PS
Planned sale
|
Moran Kyle
Chief Financial Officer
Officer
|
37,062
-44.6%
4.75
USD 176,119
|
37,062
-44.6%
|
4.75
|
USD 176,119
|
|
|
2023-02-17 |
2023-02-16 |
S
Sale
|
Vargeese Chandra
See Remarks
Officer
|
10,249
-8.8%
4.03
USD 41,303
|
10,249
-8.8%
|
4.03
|
USD 41,303
|
|
|
2023-02-17 |
2023-02-16 |
S
Sale
|
Moran Kyle
Chief Financial Officer
Officer
|
9,729
-10.9%
4.04
USD 39,305
|
9,729
-10.9%
|
4.04
|
USD 39,305
|
|
|
2023-02-17 |
2023-02-16 |
S
Sale
|
Francis Chris
See Remarks
Officer
|
10,258
-11.4%
4.03
USD 41,340
|
10,258
-11.4%
|
4.03
|
USD 41,340
|
|
|
2023-02-17 |
2023-02-16 |
S
Sale
|
BOLNO PAUL
President and CEO
Executive Director
|
29,400
-6.7%
4.04
USD 118,776
|
29,400
-6.7%
|
4.04
|
USD 118,776
|
|
|
2022-06-21 |
2022-06-16 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director
Large shareholder
|
9,480,052
+122.8%
2.15
USD 20,382,112
|
9,480,052
+122.8%
|
2.15
|
USD 20,382,112
|
|
|
2022-05-06 |
2022-05-05 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
33,501
-7.1%
1.72
USD 57,622
|
33,501
-7.1%
|
1.72
|
USD 57,622
|
|
|
2022-05-06 |
2022-05-05 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
10,867
-10.8%
1.72
USD 18,691
|
10,867
-10.8%
|
1.72
|
USD 18,691
|
|
|
2022-05-06 |
2022-05-05 |
PS
Planned sale
|
Vargeese Chandra
See Remarks
Officer
|
16,714
-13.1%
1.72
USD 28,748
|
16,714
-13.1%
|
1.72
|
USD 28,748
|
|
|
2022-05-06 |
2022-05-05 |
PS
Planned sale
|
Moran Kyle
Chief Financial Officer
Officer
|
5,021
-5.6%
1.72
USD 8,636
|
5,021
-5.6%
|
1.72
|
USD 8,636
|
|
|
2022-05-06 |
2022-05-05 |
PS
Planned sale
|
Panzara Michael A.
See Remarks
Officer
|
16,714
-13.3%
1.72
USD 28,748
|
16,714
-13.3%
|
1.72
|
USD 28,748
|
|
|
2022-02-18 |
2022-02-16 |
S
Sale
|
Moran Kyle
Chief Financial Officer
Officer
|
9,204
-11.0%
2.31
USD 21,261
|
9,204
-11.0%
|
2.31
|
USD 21,261
|
|
|
2022-02-18 |
2022-02-16 |
S
Sale
|
Francis Chris
See Remarks
Officer
|
10,123
-12.9%
2.31
USD 23,384
|
10,123
-12.9%
|
2.31
|
USD 23,384
|
|
|
2022-02-18 |
2022-02-16 |
S
Sale
|
Panzara Michael A.
See Remarks
Officer
|
10,603
-12.3%
2.31
USD 24,493
|
10,603
-12.3%
|
2.31
|
USD 24,493
|
|
|
2022-02-18 |
2022-02-16 |
S
Sale
|
BOLNO PAUL
President and CEO
Executive Director
|
33,150
-8.1%
2.32
USD 76,908
|
33,150
-8.1%
|
2.32
|
USD 76,908
|
|
|
2022-02-18 |
2022-02-16 |
S
Sale
|
Vargeese Chandra
Chief Technology Officer
Officer
|
10,603
-12.0%
2.32
USD 24,599
|
10,603
-12.0%
|
2.32
|
USD 24,599
|
|
|
2021-02-18 |
2021-02-16 |
PS
Planned sale
|
Moran Kyle
Chief Financial Officer
Officer
|
1,722
-2.4%
10.57
USD 18,202
|
1,722
-2.4%
|
10.57
|
USD 18,202
|
|
|
2021-02-18 |
2021-02-16 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
2,698
-3.3%
10.57
USD 28,518
|
2,698
-3.3%
|
10.57
|
USD 28,518
|
|
|
2021-02-18 |
2021-02-16 |
PS
Planned sale
|
Vargeese Chandra
Chief Technology Officer
Officer
|
3,145
-3.6%
10.57
USD 33,243
|
3,145
-3.6%
|
10.57
|
USD 33,243
|
|
|
2021-02-18 |
2021-02-16 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
11,205
-2.7%
10.57
USD 118,437
|
11,205
-2.7%
|
10.57
|
USD 118,437
|
|
|
2021-02-18 |
2021-02-16 |
PS
Planned sale
|
Panzara Michael A.
See Remarks
Officer
|
2,929
-3.3%
10.57
USD 30,960
|
2,929
-3.3%
|
10.57
|
USD 30,960
|
|
|
2020-09-17 |
2020-09-15 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
100,000
-26.9%
15.00
USD 1,500,000
|
100,000
-26.9%
|
15.00
|
USD 1,500,000
|
|
|
2020-08-27 |
2020-08-25 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
25,000
-8.4%
12.00
USD 300,000
|
25,000
-8.4%
|
12.00
|
USD 300,000
|
|
|
2020-07-02 |
2020-07-02 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
95,921
-26.1%
10.27
USD 985,109
|
95,921
-26.1%
|
10.27
|
USD 985,109
|
|
|
2020-07-02 |
2020-07-02 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
4,079
-1.1%
10.91
USD 44,502
|
4,079
-1.1%
|
10.91
|
USD 44,502
|
|
|
2020-07-02 |
2020-07-02 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
43,068
-13.7%
10.26
USD 441,878
|
43,068
-13.7%
|
10.26
|
USD 441,878
|
|
|
2020-07-02 |
2020-07-02 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
4,509
-1.4%
10.82
USD 48,787
|
4,509
-1.4%
|
10.82
|
USD 48,787
|
|
|
2020-02-20 |
2020-02-18 |
PS
Planned sale
|
Panzara Michael A.
Chief Medical Officer
Officer
|
2,981
-7.0%
7.85
USD 23,401
|
2,981
-7.0%
|
7.85
|
USD 23,401
|
|
|
2020-02-20 |
2020-02-18 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
11,451
-3.5%
7.85
USD 89,890
|
11,451
-3.5%
|
7.85
|
USD 89,890
|
|
|
2020-02-20 |
2020-02-18 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
2,708
-8.0%
7.85
USD 21,258
|
2,708
-8.0%
|
7.85
|
USD 21,258
|
|
|
2020-02-20 |
2020-02-18 |
PS
Planned sale
|
Vargeese Chandra
Senior VP, Drug Discovery
Officer
|
3,188
-7.9%
7.85
USD 25,026
|
3,188
-7.9%
|
7.85
|
USD 25,026
|
|
|
2020-02-05 |
2020-02-03 |
PS
Planned sale
|
Gaiero David G
Interim CFO
|
651
-9.2%
7.00
USD 4,557
|
651
-9.2%
|
7.00
|
USD 4,557
|
|
|
2019-12-05 |
2019-12-03 |
PS
Planned sale
|
Vargeese Chandra
Senior VP, Drug Discovery
Officer
|
6,000
-13.0%
35.00
USD 210,000
|
6,000
-13.0%
|
35.00
|
USD 210,000
|
|
|
2019-11-22 |
2019-11-20 |
S
Sale
|
Verdine Gregory L.
Non-Executive Director
|
2,609
-8.0%
32.74
USD 85,419
|
2,609
-8.0%
|
32.74
|
USD 85,419
|
|
|
2019-11-22 |
2019-11-20 |
S
Sale
|
Verdine Gregory L.
Non-Executive Director
|
3,400
-9.4%
31.59
USD 107,406
|
3,400
-9.4%
|
31.59
|
USD 107,406
|
|
|
2019-11-22 |
2019-11-20 |
S
Sale
|
Verdine Gregory L.
Non-Executive Director
|
24,030
-40.0%
30.27
USD 727,388
|
24,030
-40.0%
|
30.27
|
USD 727,388
|
|
|
2019-07-09 |
2019-07-05 |
PS
Planned sale
|
Panzara Michael A.
Chief Medical Officer
|
445
-1.0%
27.26
USD 12,131
|
445
-1.0%
|
27.26
|
USD 12,131
|
|
|
2019-07-09 |
2019-07-05 |
PS
Planned sale
|
Panzara Michael A.
Chief Medical Officer
|
2,613
-5.8%
26.88
USD 70,237
|
2,613
-5.8%
|
26.88
|
USD 70,237
|
|
|
2019-03-19 |
2019-03-15 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
1,763
-0.5%
46.00
USD 81,098
|
1,763
-0.5%
|
46.00
|
USD 81,098
|
|
|
2019-03-19 |
2019-03-15 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
8,237
-2.4%
45.22
USD 372,477
|
8,237
-2.4%
|
45.22
|
USD 372,477
|
|
|
2019-03-19 |
2019-03-15 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
5,065
-1.5%
45.89
USD 232,433
|
5,065
-1.5%
|
45.89
|
USD 232,433
|
|
|
2019-03-19 |
2019-03-15 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
34,935
-9.2%
45.45
USD 1,587,796
|
34,935
-9.2%
|
45.45
|
USD 1,587,796
|
|
|
2019-03-11 |
2019-03-11 |
PS
Planned sale
|
Panzara Michael A.
Franchise Lead, Neurology
|
7,000
-13.4%
48.00
USD 336,000
|
7,000
-13.4%
|
48.00
|
USD 336,000
|
|
|
2019-02-21 |
2019-02-19 |
PS
Planned sale
|
Panzara Michael A.
Franchise Lead, Neurology
Officer
|
1,837
-4.7%
36.84
USD 67,674
|
1,837
-4.7%
|
36.84
|
USD 67,674
|
|
|
2019-02-21 |
2019-02-19 |
PS
Planned sale
|
Regnante Keith
Chief Financial Officer
Officer
|
1,298
-7.6%
36.84
USD 47,818
|
1,298
-7.6%
|
36.84
|
USD 47,818
|
|
|
2019-02-21 |
2019-02-19 |
PS
Planned sale
|
Vargeese Chandra
Senior VP, Drug Discovery
Officer
|
2,055
-7.5%
36.84
USD 75,706
|
2,055
-7.5%
|
36.84
|
USD 75,706
|
|
|
2019-02-21 |
2019-02-19 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
1,709
-7.7%
36.84
USD 62,959
|
1,709
-7.7%
|
36.84
|
USD 62,959
|
|
|
2019-02-21 |
2019-02-19 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
119
-0.0%
37.47
USD 4,458
|
119
-0.0%
|
37.47
|
USD 4,458
|
|
|
2019-02-21 |
2019-02-19 |
PS
Planned sale
|
BOLNO PAUL
President and CEO
Executive Director
|
7,614
-2.7%
36.38
USD 276,997
|
7,614
-2.7%
|
36.38
|
USD 276,997
|
|
|
2019-01-28 |
2019-01-24 |
B
Purchase
|
RA CAPITAL MANAGEMENT, LLC
Non-Executive Director
Large shareholder
|
263,158
+3.5%
38.00
USD 10,000,004
|
263,158
+3.5%
|
38.00
|
USD 10,000,004
|
|
|
2018-11-16 |
2018-11-14 |
S
Sale
|
Verdine Gregory L.
Non-Executive Director
|
4,300
-6.7%
39.52
USD 169,936
|
4,300
-6.7%
|
39.52
|
USD 169,936
|
|
|
2018-11-16 |
2018-11-14 |
S
Sale
|
Verdine Gregory L.
Non-Executive Director
|
10,700
-14.3%
38.59
USD 412,913
|
10,700
-14.3%
|
38.59
|
USD 412,913
|
|
|
2018-09-26 |
2018-09-25 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
10,543
-32.3%
56.00
USD 590,408
|
10,543
-32.3%
|
56.00
|
USD 590,408
|
|
|
2018-09-26 |
2018-09-24 |
PS
Planned sale
|
Vargeese Chandra
Senior VP, Drug Discovery
Officer
|
3,000
-9.9%
55.00
USD 165,000
|
3,000
-9.9%
|
55.00
|
USD 165,000
|
|
|
2018-09-26 |
2018-09-24 |
PS
Planned sale
|
Regnante Keith
Chief Financial Officer
Officer
|
29,500
-63.5%
55.00
USD 1,622,500
|
29,500
-63.5%
|
55.00
|
USD 1,622,500
|
|
|
2018-09-26 |
2018-09-24 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
1,032
-4.5%
56.00
USD 57,792
|
1,032
-4.5%
|
56.00
|
USD 57,792
|
|
|
2018-07-11 |
2018-07-09 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
596
-2.6%
38.22
USD 22,779
|
596
-2.6%
|
38.22
|
USD 22,779
|
|
|
2018-07-11 |
2018-07-09 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
23,900
-52.0%
37.25
USD 890,275
|
23,900
-52.0%
|
37.25
|
USD 890,275
|
|
|
2018-06-01 |
2018-06-01 |
PS
Planned sale
|
Francis Chris
See Remarks
Officer
|
24,496
-52.6%
48.00
USD 1,175,808
|
24,496
-52.6%
|
48.00
|
USD 1,175,808
|
|
